Pre-clinical Data Suggest Soliton's RAP Technology Can Help Liver Fibrosis

A pre-clinical study in animals demonstrates positive results for Soliton’s RAP device as a potential treatment for liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse (RAP) therapy reduced the effects of induced liver fibrosis seven days following completion of carbon tetrachloride (CCL4) induction by 42%. In addition, post-treatment histology slides stained with picrosirius red (PSR) showed a lower percentage of fibrosis from a single 2-minute RAP treatment compared to the Control group.  

"While we maintain a tight focus on our upcoming commercial launch of the RAP device in both cellulite reduction and tattoo removal, we believe exploring new indications with large markets and significant unmet needs, such as liver fibrosis, offers potential for increasing long-term shareholder value," says Brad Hauser, President and CEO of Soliton. "One of the things that distinguishes Soliton is the strength of the science that underlies RAP. This latest research underscores just how unique our acoustic shockwave technology is and how potentially important its applications could be.  We look forward to continuing to examine the strong promise the RAP technology offers across many fibrotic conditions."

The RAP device is currently cleared by the FDA for temporary improvement in the appearance of cellulite. The RAP device is also indicated for use as an accessory to the 1064nm Q-Switched laser for black ink tattoo removal in Fitzpatrick Skin Type I-III patients. The technology is not cleared for the treatment of liver fibrosis.